YYB101

DRUG2 trials

Sponsors

CellabMED

Conditions

Colorectal Cancer MetastaticColorectal Cancer RecurrentSolid Tumors

Phase 1

Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

CompletedNCT02499224

CellabMEDSolid Tumors

Start: 2015-07-13End: 2018-07-04Updated: 2021-05-13

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

CompletedNCT04368507

CellabMEDColorectal Cancer Metastatic, Colorectal Cancer Recurrent

Start: 2019-08-09End: 2021-12-21Updated: 2022-11-14

Related Papers

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Therapeutic Advances in Medical Oncology2020-01-0114 citations

First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.

Journal of Clinical Oncology2018-05-201 citations